Ontario-based cannabis firm, Canopy Growth Corporation has announced a new partnership with American entrepreneur and television personality, Martha Stewart.
Stewart will be assisting Canopy with the development and positioning of a variety of new cannabidiol (CBD) products. Canopy approached Stewart about the partnership in 2018 because of her experience in publishing, broadcasting, merchandising, and her keen understanding of consumer needs.
“I am delighted to establish this partnership with Canopy Growth and share with them the knowledge I have gained after years of experience in the subject of living,” said Stewart in a statement. “I’m especially looking forward to our first collaboration together, which will offer sensible products for people’s beloved pets.”
Canopy Animal Health (CAH) began conducting clinical trials on the treatment of animal anxiety with CBD in 2018 with approval from the Veterinary Drug Directorate of Health Canada. CBD used in the trials comes from at Canopy Growth’s facility in Smith Falls.
“Our passion to create safe and effective products for animals is driven by the love we share for our pets,” stated Canopy Health Innovations Managing Director, Marc Wayne. “The use of natural-occurring cannabinoids as a therapy for companion animals is a logical new forefront of medical discovery and the research we are working on at CAH is world leading.”
“These trial approvals mark a significant milestone on the journey of making cannabis-based drugs accepted and recommended by veterinarians,” he said.
Canopy Growth chairman and co-CEO, Bruce Linton said that he is excited to be working alongside Stewart to help develop and market new CBD products for both humans and animals.
Canopy is planning to invest up to $150 million in an industrial hemp park in New York State which they intend to be their first hemp facility in the United States.
